Vaccinex (NASDAQ:VCNX) Stock Price Down 3.4% – What’s Next?

Vaccinex, Inc. (NASDAQ:VCNX)’s share price traded down 3.4% during mid-day trading on Tuesday . The stock traded as low as $1.02 and last traded at $1.06. 4,064 shares were traded during mid-day trading, an increase of 1% from the average session volume of 4,016 shares. The stock had previously closed at $1.10.

Vaccinex Stock Down 3.4 %

The firm has a market cap of $2.76 million, a price-to-earnings ratio of -0.02 and a beta of 1.10. The stock’s 50 day moving average is $2.79 and its 200 day moving average is $4.23.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Vaccinex stock. Point72 Asset Management L.P. increased its holdings in Vaccinex, Inc. (NASDAQ:VCNX) by 42.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 166,000 shares of the company’s stock after purchasing an additional 49,454 shares during the quarter. Point72 Asset Management L.P. owned 9.60% of Vaccinex worth $564,000 at the end of the most recent quarter. 50.11% of the stock is owned by institutional investors and hedge funds.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.